Cytomx Therapeutics, Inc.

Bristol-myers Squibb Compnay

Ph Pharma Co., Ltd.

Kimberly Ann Tipton

James William West

Luc Roland Desnoyers

Jason Gary Sagert

Jonathan Alexander Terrett

Shrikant Deshpande

Shweta Singh

Annie Yang Weaver

John J Englehardt

Sanjeev Satyal

Vasu Jammalamadaka

Hoyoung Huh

Chanty Mariategue Chan

Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.

Activatable anti-CTLA-4 antibodies and uses thereof

The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

Thailanstatin analogs

The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

Growing community of inventors

San Francisco, CA, United States of America

Kimberly Ann Tipton